The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...

Considering the good news, is Vertex heading to $600? Let's find out.

Vertex Pharmaceuticals Incorporated ( VRTX) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDT ...

Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs. Vertex is the global leader in ...

KING OF PRUSSIA, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Thursday afternoon. Here’s what you need to know. Vertex Pharmaceuticals met analysts’ revenue expectations last ...

Imagine that you want to know the most efficient way to make a torus—a doughnut-shaped mathematical object—from origami paper. But this torus, which is a surface, looks drastically different than the ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Given the rapidly evolving landscape of Artificial Intelligence, one of the biggest hurdles tech leaders often come across is transitioning from being “experimental” to being “enterprise-ready”. While ...

It is hard to productionalize data science use cases, especially because the journey from experimentation is lacking standardisation. Thus, this project aims at boosting, scalability, productivity and ...

- Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim ...